Zogenix, Inc. Provides Update on Zohydro™ ER NDA

Published: Oct 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced that it has been informed today by the U.S. Food and Drug Administration (FDA) that an action letter on the New Drug Application (NDA) for ZohydroTM ER (hydrocodone bitartrate) extended-release capsules could follow after a further delay of short duration. The FDA had previously informed the company that it expected to issue an action letter over the summer. The original PDUFA goal date was March 1, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news